Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Nabriva Therapeutics
Nabriva Therapeutics
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Pharmaceutical
Nabriva Therapeutics appoints Will Sargent as Vice President of Commercial Strategy and Investor Relations
He will lead development of commercial strategy for the launch of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP)
Research & Development
Elyse Seltzer joins Nabriva Therapeutics as Chief Medical Officer
Dr William Prince moves to Senior Vice President, Clinical Science
Infection Control
Nabriva Therapeutics secures financing of up to US$120m
To advance development of antibiotics for the treatment of infections caused by resistant gram-positive and gram-negative bacteria
Pharmaceutical
Nabriva Therapeutics strengthens board and management team
Charles Rowland and Dr Steven Gelone join the company
Research & Development
Nabriva Therapeutics hires Colin Broom as CEO
Also establishes new US subsidiary in the Philadelphia area
Subscribe now